Synovial sarcoma: Evaluation of response to treatment with gemcitabin and docetaxel.

10564 Background: Synovial Sarcoma (SS) is one of the more common subtypes of soft tissue sarcomas, comprising 8-10% of this entity. It is well known that SS responds well to adriamycin/ifosfamide (AI) therapies, however responses to gemcitabine/docetaxel (GT) combination have not been well documented, although commonly used in practice. This study aimed to evaluate response to GT in patients with SS. Methods: We retrospectively reviewed medical records of patients diagnosed with SS from 2000 to 2012. All patients had confirmed SS by pathology review. Only patients who were metastatic and treated with GT concurrently were included. Results: The study included 51 patients with metastatic disease who received GT concurrently. Majority of patients were white (69%), with a mean age of 42 years (SD 15) when receiving GT. Median time from initial diagnosis to first metastasis was 15 months. Median overall survival from first metastasis was 2.3 years (95% CI 1.8-3.0 years). The majority of patients (96%) had rec...